ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Juno, Novartis Settle CAR Patent Lawsuit

by Ann M. Thayer
April 13, 2015 | APPEARED IN VOLUME 93, ISSUE 15

Novartis and Juno Therapeutics have agreed to settle patent litigation around chimeric antigen receptor (CAR) technology. Novartis will pay $12.3 million up front and a portion of any future royalties to the Seattle-based start-up. In 2013, Juno licensed CAR technology from, and will now share payments with, St. Jude Children’s Research Hospital. The litigation began in 2012 as a dispute between St. Jude and the University of Pennsylvania, which has licensed technology to Novartis. The settlement will allow each party to advance its own cancer immunotherapies and “rewards the investigators on whose insights those developments are based,” according to Juno CEO Hans Bishop.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment